Skip to content

Evaluating the effect of gargling with Hydrogen Peroxide 1% and Povidine Iodine 0.25% on viral load of SARS-CoV-2 in covid19 patients

Evaluating the effect of gargling with Hydrogen Peroxide 1% and Povidine Iodine 0.25% on viral load of SARS-CoV-2 in covid19 patients ; A pilot randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201212049681N1
Enrollment
60
Registered
2021-02-28
Start date
2021-01-20
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. severe acute respiratory syndrome corona virus

Interventions

Intervention 1: intervention group: Group A (n=20) patients on 10 ml gargle using 0.25% Povidone-Iodine, for 20-30 seconds,. Intervention 2: intervention group: Group B (n=20) patients will be subject

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: having age 18-50, those who are hospitalized and have confirmed covid 19 viral contamination.

Exclusion criteria

Exclusion criteria: having any systemic disease or medications that may interact with Povidine Iodine and-or Hydrogen Peroxide patients who are not feeling well, not cooperative patients, and those who don’t want to participate in the study

Design outcomes

Primary

MeasureTime frame
Viral load before the intervention, viral load after the intervention. Timepoint: before intervention and 5-10 minutes after intervention. Method of measurement: real-time reverse transcriptase polymerase chain reaction (rRT-PCR).

Secondary

MeasureTime frame
Viral transmission in saliva. Timepoint: before the intervention and 5-10 minutes after the intervention. Method of measurement: real-time reverse transcriptase polymerase chain reaction (rRT-PCR).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Rajabzadeh

Shiraz University of Medical Sciences

adla@sums.ac.ir+98 71 3832 3435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026